Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.530
-0.150-1.55%
Volume:74.46M
Turnover:712.88M
Market Cap:109.80B
PE:24.08
High:9.715
Open:9.625
Low:9.505
Close:9.680
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.52
T/O Rate:0.65%
Dividend:0.34
Dividend Rate:3.53%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.51
PE(LYR):24.08
PS:3.01

Loading ...

CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China

Bulletin Express
·
Aug 28

CSPC Pharmaceutical Group Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 28

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live
·
Aug 27

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

Stock News
·
Aug 27

CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes

Bulletin Express
·
Aug 27

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

Reuters
·
Aug 27

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS
·
Aug 27

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Aug 27

CSPC PHARMA: DFZQ Disposes of Shares, Long Position Falls to 4.93%

HK Disclosure
·
Aug 27

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.
·
Aug 27

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live
·
Aug 26

CSPC Pharma’s EGFR-Targeted ADC SYS6010 Achieves Primary PFS Endpoint in Phase III NSCLC Trial

Bulletin Express
·
Aug 26

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Aug 26

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Aug 26

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

Reuters
·
Aug 26

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

Stock News
·
Aug 26

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 26

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Aug 26